Liver cirrhosis patients get tested on common blood thinners

NCT ID NCT04874428

Recruiting now Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study looks at how two common blood thinners, rivaroxaban and apixaban, behave in people with compensated liver cirrhosis. 24 participants receive a single dose of one drug, and researchers measure drug levels and blood clotting markers over 12 hours. The goal is to gather safety and dosing information, not to treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rivaroxaban and apixaban (blood thinners)
What this could lead to: If successful, this could help doctors understand how to safely use these blood thinners in people with liver cirrhosis, potentially reducing clot risks.
What could go wrong: This is a very early, small phase 1 study with only 24 participants and single doses, so results may not apply to long-term use or broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder cirrhosis of liver Embolism and Thrombosis liver disorder Thromboembolism vascular disorder venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Locations

Department of Visceral Surgery and Medicine, University Hospital Inselspital, Berne
RECRUITING

Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.